Subcutaneous tocilizumab treatment in patients with severe COVID-19–related cytokine release syndrome: An observational cohort study

Background: Patients with severe coronavirus disease 2019 (COVID-19) have elevated levels of acute phase reactants and inflammatory cytokines, including interleukin-6, indicative of cytokine release syndrome (CRS). The interleukin-6 receptor inhibitor tocilizumab is used for the treatment of chimeri...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Antonio Mastroianni, Sonia Greco, Giovanni Apuzzo, Salvatore De Santis, Carmela Oriolo, Alfredo Zanolini, Luciana Chidichimo, Valeria Vangeli
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2020-07-01
coleção:	EClinicalMedicine
Assuntos:	Cytokine release syndrome Coronavirus disease 2019 Tocilizumab
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2589537020301541
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!